Latest News

The two complications, which appear to be unrelated, also appear to be unrelated to clinician experience.

Post date: 09/29/2020 - 16:57

MDedge ObGyn

“Unclear how much of the increase in child cases is due to increased testing capacity,” AAP says.

Post date: 09/29/2020 - 15:47

MDedge Pediatrics

Requests to a telemedicine service for self-managed abortion care increased in the wake of COVID-19 clinic shutdowns.

Post date: 09/29/2020 - 15:23

MDedge ObGyn

But physicians are adapting and still finding joy in treating patients.

Post date: 09/29/2020 - 14:07

MDedge Internal Medicine

New guideline articulates a broad approach to treatment that needs to be tailored to individual patients.

Post date: 09/29/2020 - 14:03

MDedge Rheumatology

Atezolizumab may improve survival when it’s added to nab-paclitaxel but not paclitaxel, studies suggest.

Post date: 09/28/2020 - 14:07

MDedge Hematology and Oncology

A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D patients.

Post date: 09/28/2020 - 12:32

MDedge Endocrinology

Results of two new studies provide further evidence that exercise reduces all-cause and cardiovascular mortality in those with type 2 diabetes.

Post date: 09/28/2020 - 12:20

MDedge Endocrinology

Simulation study supports value of mifepristone and misoprostol for medical management of miscarriage.

Post date: 09/28/2020 - 09:45

MDedge ObGyn

New therapies for this common and challenging condition may be on the horizon.

Post date: 09/28/2020 - 09:41

MDedge ObGyn

Success in increasing the survival of children with SCD has not been translated into similar success as they become adults.

Post date: 09/28/2020 - 09:31

MDedge Hematology and Oncology

Three agents that address major unmet needs move to phase 3.

Post date: 09/25/2020 - 14:49

MDedge Psychiatry

“Enhanced responsiveness to food cues may be a mediating mechanism underlying overeating in ADHD,” said Elizabeth Martin, MSc.

Post date: 09/25/2020 - 14:08

MDedge Psychiatry

Data suggest fewer people are dying from stomach cancer, but in some countries, the risk of colorectal cancer death is increasing or declining much more slowly than other causes of premature death.

Post date: 09/25/2020 - 11:49

MDedge Hematology and Oncology

A systematic review provides limited evidence to support oral beta-blockers as a treatment for rosacea-associated facial erythema and flushing.

Post date: 09/25/2020 - 11:41

MDedge Dermatology

"While benzodiazepines are important therapies for many Americans, they are also commonly abused and misused," said Commissioner Stephen M. Hahn, MD.

Post date: 09/25/2020 - 11:20

MDedge Psychiatry

Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25.

Post date: 09/25/2020 - 11:12

MDedge Endocrinology

Registry data revealed factors associated with intraoperative and postoperative complications.

Post date: 09/25/2020 - 11:05

MDedge Hematology and Oncology

The proportion of chats handled at the crisis hotline was 48% greater in the first half of 2020, compared with a year earlier.

Post date: 09/25/2020 - 09:23

MDedge Psychiatry

Adverse effects – particularly frequency of infection – were increased in the high-dose group.

Post date: 09/25/2020 - 09:06

MDedge Neurology

Rare but serious and possibly life-threatening autoimmune events that have recently been linked to the drug.

Post date: 09/24/2020 - 16:45

MDedge Neurology

Dr. Marcy B. Bolster addresses common patient concerns about bisphosphonate use.

Post date: 09/24/2020 - 16:31

MDedge Rheumatology

A higher percentage of total B cells, and in particular plasmablasts, could be a very predictive biomarker for autoimmunity after alemtuzumab treatment.

Post date: 09/24/2020 - 15:07

MDedge Neurology

“We will always observe standard precautions, which include hand hygiene, gloves, hair and eye cover, medical mask, and face shield,” Dr. Charles Griffis said.

Post date: 09/24/2020 - 14:35

CHEST Physician

Phase 3 trial results support the use of nivolumab as first-line or adjuvant therapy for gastric or gastroesophageal junction cancers.

Post date: 09/24/2020 - 14:31

MDedge Hematology and Oncology